LONDON (Reuters) - GlaxoSmithKline Plc said on Wednesday early U.S. sales of its new diet pill, Alli, were exceeding expectations, vindicating its decision to maintain a strong presence in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback